<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3432">
  <stage>Registered</stage>
  <submitdate>12/01/2012</submitdate>
  <approvaldate>12/01/2012</approvaldate>
  <nctid>NCT01511692</nctid>
  <trial_identification>
    <studytitle>Effect of Liraglutide Compared to Glimepiride on Appetite in Subjects With Type 2 Diabetes</studytitle>
    <scientifictitle>A 4 Week Single Center, Double-dummy, Randomised Double-blind, Balanced Incomplete Latin Square Design Study to Evaluate the Effects of Liraglutide on Appetite in Subjects With Type 2 Diabetes Compared to Glimepiride and Placebo</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2006-000377-30</secondaryid>
    <secondaryid>NN2211-1589</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Diabetes</healthcondition>
    <healthcondition>Diabetes Mellitus, Type 2</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - liraglutide
Treatment: drugs - placebo
Treatment: drugs - placebo
Treatment: drugs - glimepiride

Experimental: Lira --&gt; placebo - 

Placebo Comparator: Placebo --&gt; glim - 

Active Comparator: Glim --&gt; lira - 


Treatment: drugs: liraglutide
1.8 mg/day injected subcutaneously for 4 weeks

Treatment: drugs: placebo
Liraglutide placebo, injected subcutaneously for 4 weeks

Treatment: drugs: placebo
Glimepiride placebo, dose individually adjusted, administered orally for 4 weeks

Treatment: drugs: glimepiride
Dose individually adjusted, administered orally for 4 weeks

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The energy intake at a standardised buffet meal with a preload paradigm quantified using Foodworks 2.10</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>The energy intake at a standardised buffet meal without a preload paradigm quantified using Foodworks 2.10</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Macronutrient distribution of food consumed at a standardised buffet meal with a preload paradigm quantified using Foodworks 2.10</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Macronutrient distribution of food consumed at a standardised buffet meal without a preload paradigm quantified using Foodworks 2.10</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Total duration of eating at the buffet meal (satiation)</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Weight</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Waist circumference</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Adverse events</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Type 2 diabetes mellitus

          -  Diet-treated subjects and/or subjects with type 2 diabetes in OAD (oral anti-diabetic
             drug) mono-therapy

          -  HbA1c for diet-treated subjects: HbA1c between 6.5-10.0% (both inclusive) and for OAD
             treated subjects: HbA1c between 6.5-9.5% (both inclusive)

          -  Body mass index (BMI) between 27-40 kg/m^2 (both inclusive)

          -  Subjects should have a stable body weight for at least 3 months prior to screening (as
             documented by a weight within 3 to 6 months, prior to screening that is within 15% of
             the screening weight)

          -  Euthyroid subjects

          -  Subjects should be unrestrained eaters</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Recurrent severe hypoglycaemia

          -  Impaired liver function

          -  Impaired renal function

          -  Cardiac problems

          -  Uncontrolled treated/untreated hypertension

          -  Known or suspected allergy to trial products or related products

          -  Use of any drug (except for OADs), which in the investigator's opinion could interfere
             with the subject's glucose level or body weight

          -  Active hepatitis B and/or active hepatitis C

          -  Positive HIV (human immunodeficiency virus) antibodies

          -  Known or suspected abuse of alcohol or narcotics

          -  Habitual excessive consumption of methylxanthine-containing beverages and foods
             (coffee, tea, cola drinks, chocolate) as judged by the Investigator</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/11/2005</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>43</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/09/2007</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA</recruitmentstate>
    <hospital>Novo Nordisk Investigational Site - Adelaide</hospital>
    <postcode>5005 - Adelaide</postcode>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Neuss</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Novo Nordisk A/S</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This trial is conducted in Europe and Oceania. The aim of this trial is to assess the effects
      of liraglutide on energy intake in subjects with type 2 diabetes.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01511692</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Global Clinical Registry (GCR, 1452)</name>
      <address>Novo Nordisk A/S</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>